Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + prednisolone with or without zoledronic acid and/or strontium-89 in metastatic hormone-refractory prostate cancer
ISRCTN12808747Phase 3Completed
- Sponsor
- University of Birmingham
- Start
- Apr 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of docetaxel, prednisolone, zoledronic acid and strontium-89 in prostate cancer (PCa) and castration-resistant prostate cancer (CRPC) (4 arms), sponsored by University of Birmingham. Primary endpoints: Toxicity and tolerability of docetaxel + synchronous zoledronic acid, Toxicity and tolerability of docetaxel + strontium-89 and 1 more. Started Apr 2007; status: completed.
02
Drugs
docetaxelprednisolonezoledronic acidstrontium-89
03
Conditions
prostate cancer (PCa)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on ISRCTN12808747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12808747.